Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Google Secures Pentagon AI Deal for Classified Projects 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S. 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
PLYMOUTH, Minn., Feb. 10, 2016 -- Entellus Medical, Inc. (NASDAQ:ENTL), a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients, today announced that it will release its financial results for the fourth quarter and year-end 2015 after the close of trading on Wednesday, February 24, 2016. The Company’s management team will host a corresponding conference call beginning at 3:30pm CT/4:30pm ET to discuss the financial results and recent business developments.
Individuals interested in listening to the conference call may do so by dialing (877) 930-5751 for domestic callers or (253) 336-7277 for international callers, using Conference ID: 38482495. To listen to a live webcast, please visit the investor relations section of the Entellus Medical website at: www.entellusmedical.com.
A replay of the call will be available beginning February 24, 2016 at 6:30pm CT/7:30pm ET through midnight ET on February 25, 2016. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 38482495. The webcast will also be available on the Entellus Medical website for one month following the completion of the call.
About Entellus Medical, Inc.
Entellus Medical is a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis patients. The Entellus Medical platform of products provides physicians with solutions to aid in the diagnosis and treatment of patients suffering from chronic sinusitis. Its XprESS family of products is used by ENT physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation. When used as a stand-alone therapy, Entellus Medical's balloon sinus dilation products are the only devices proven in a sufficiently powered prospective, multicenter, randomized, controlled trial to be as effective as functional endoscopic sinus surgery ("FESS"). Patients treated with Entellus Medical's products in this trial in the ENT physician's office also experienced faster recovery, less bleeding at discharge, less use of prescription pain medication and fewer post-procedure debridements than patients receiving FESS. In addition to its XprESS line of products, Entellus Medical has recently introduced additional products designed to aid in the diagnosis, treatment and post-operative care of patients suffering from chronic sinusitis. For more information, please visit the Company's website at www.entellusmedical.com.
Contact: Lynn Pieper Lewis 415-309-5999 [email protected]
